Six-Month Outcomes: Tangible Metabolic Gains Weight : 11% reduction Fasting insulin : Decreased from 36.1 to 21.4 Fasting glucose : Improved HOMA-IR : Down substantially A1C : Reduced toward normal range Dyslipidemia : Improved Liver enzymes : Improved Binge eating : From 12 times/week to 12 times/month, commonly stress-triggered Physical activity : Maintained high-volume training with added walks Sleep and alcohol : Sleep stable
Join a Trial Testing a New Medication for Obesity and Weight-Related Conditions If you live with excess weight, you may be eligible for a clinical trial testing survodutide, a new GLP-1 medication in development that helps people lose weight
-Arrestin-biased agonists of the GLP-1 receptor from -amino acid residue incorporation into GLP-1 analogues
Its not one and done its about keeping your energy stable long-term
For more information, see Getting a GLP1 Prescription
5 combined L-BSO with sulphasalazine or auranofin (a gold salt used in the treatment of rheumatoid arthritis) to inhibit both glutathione- and thioredoxin-dependent antioxidant pathways, triggering synergistic cancer cell death (Fig